MDK Medical to Make Its Medical Device Healthcare Business a New Core Business
First written in FY2019. 4 of 13 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MaterialisedAnnual report
「However, because it became clear that the receivable could not be collected due to delays in clinical trials related to product development by Med Alliance SA, the remaining ¥488 million of the amount recognized as an asset was recorded as an extraordinary loss.」
Following the exit from the healthcare investment, it became clear that the receivable could not be collected due to delays in clinical trials related to product development, resulting in an actual investment-related loss of ¥488 million. - FY2023-Q1RestatedAnnual report
「At a meeting of the Board of Directors held on 13 October 2022, the Company resolved to transfer all shares of M.A. Med Alliance SA held by the Company to Bayou Holdings Parent, L.P., and entered into a share transfer agreement with that company dated 28 October 2022.」
The agreement to transfer all shares of Med Alliance SA, the expected completion of the transfer in October 2023, and the consideration structure involving a one-time payment, completion of regulatory procedures and achievement of sales targets under certain conditions have been reconfirmed. - FY2022-Q4Exit from the investment formalized through execution of the Med Alliance share transfer agreementAnnual report
「At a meeting of the Board of Directors held on 13 October 2022, the Company resolved to transfer all shares of M.A. Med Alliance SA held by the Company to Bayou Holdings Parent, L.P., and entered into a share transfer agreement with that company dated 28 October 2022. “Expected completion of transfer: October 2023.” “Transfer consideration: Subject to the satisfaction of certain legal and regulatory closing conditions, the shareholders of Med Alliance SA will be entitled to receive a one-time payment of US$200 million upon completion of the transfer. In addition, they will be entitled to receive up to US$125 million upon completion by 2029 of regulatory procedures related to product development and up to US$775 million upon achievement of sales targets. As the Company holds approximately 9% of the shares of Med Alliance SA, it will be entitled to receive amounts corresponding to its shareholding ratio from the one-time payment and other consideration described above.”」
Regarding the Med Alliance shares held after the transfer of MDK Medical, the Company entered into an agreement to transfer all shares, formalizing the exit from its healthcare investment. Completion of the transfer was scheduled for October 2023, with consideration varying according to closing conditions, completion of regulatory procedures by 2029 and achievement of sales targets. - FY2022-Q2DroppedAnnual report
「During the current second-quarter consolidated accounting period, all shares and other interests in MDK Medical Co., Ltd. were transferred, and the company was excluded from the scope of consolidation.」
The transfer of all shares and other interests in MDK Medical was completed on 18 March 2022, and the previous initiative to make the healthcare business a new core business was removed from the Group's consolidation. - FY2022-Q1DroppedAnnual report
「At a meeting of the Board of Directors held on 2 February 2022, the Company resolved to transfer all shares of consolidated subsidiary MDK Medical Co., Ltd. held by the Company to M.A. Med Alliance SA, and entered into a share transfer agreement with that company on the same date.」
The Group's initiative to make MDK Medical a new core business moved toward termination following the resolution to transfer all of its shares. - FY2021AdvancedAnnual report
「In the Human Infrastructure Business segment, operating loss was ¥407 million, compared with an operating loss of ¥327 million in the same period of the previous year, as subsidiary MDK Medical Co., Ltd. recorded expenses related to medical device clinical trials. Patient enrollment in the clinical trial was completed in September 2021, and follow-up observation is currently under way.」
Following the start of clinical trials, MDK Medical's medical device development progressed in September 2021 to completion of patient enrollment and the follow-up observation stage. Operating loss widened due to clinical trial expenses. - FY2021-Q3Operating loss widened after clinical trials beganAnnual report
「In the Human Infrastructure Business segment, operating loss was ¥314 million, compared with an operating loss of ¥161 million in the same period of the previous year, as subsidiary MDK Medical Co., Ltd. began clinical trials of medical devices.」
MDK Medical remains in the clinical trial stage, but operating loss widened from ¥161 million in the same period of the previous year to ¥314 million due to upfront expenses. - FY2021-Q2AdvancedAnnual report
「In the Human Infrastructure Business segment, operating loss was ¥202 million, compared with an operating loss of ¥102 million in the same period of the previous year, as subsidiary MDK Medical Co., Ltd. began clinical trials of medical devices.」
MDK Medical moved from the clinical trial preparation stage to the stage of commencing medical device clinical trials, making its activities toward commercialization of the healthcare business more concrete. - FY2021-Q1AdvancedAnnual report
「In the Human Infrastructure Business segment, operating loss was ¥109 million, compared with an operating loss of ¥46 million in the same period of the previous year, as subsidiary MDK Medical Co., Ltd. recorded expenses related to medical device clinical trials.」
MDK Medical moved into the stage of recording clinical trial expenses, making its upfront activities toward commercialization of the healthcare business more concrete. - FY2020-Q3RestatedAnnual report
「In the Other Businesses segment, operating loss was ¥161 million as subsidiary MDK Medical Co., Ltd. began full-scale preparations for clinical trials of medical devices.」
MDK Medical continues preparing for medical device clinical trials and posted an operating loss of ¥161 million during this initial stage. - FY2020-Q2RestatedAnnual report
「In the Other Businesses segment, operating loss was ¥102 million as subsidiary MDK Medical Co., Ltd. began full-scale preparations for clinical trials of medical devices.」
MDK Medical continues preparing for medical device clinical trials and posted an operating loss of ¥102 million due to upfront investment. - FY2020-Q1AdvancedAnnual report
「In the Other Businesses segment, operating loss was ¥46 million as subsidiary MDK Medical Co., Ltd. began full-scale preparations for clinical trials of medical devices.」
MDK Medical began full-scale preparations for medical device clinical trials, moving into the initial stage toward commercialization of the healthcare business. - FY2019First statedAnnual report
「During the current consolidated fiscal year, the Company established MDK Medical Co., Ltd. to enter the healthcare business as a new core business. Medical device regulations require upfront investment toward commercialization, including clinical trials before products can be marketed, but the Company expects the business to contribute to results from the fiscal year ending September 2023. Through an investment in an overseas medical device venture, MDK Medical has obtained exclusive distribution rights in Japan for products developed by that company.」
The Company established MDK Medical and announced plans to enter the healthcare business through investment in an overseas medical device venture and acquisition of exclusive distribution rights in Japan. While commercialization requires upfront investment, including clinical trials, the business is expected to contribute to results from the fiscal year ending September 2023.